MBX Biosciences - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue

Sumitomo Forestry expands U.S. housing footprint with $4.5bn Tri Pointe Homes acquisition

Applied Optoelectronics Inc. Texas expansion marks next phase in optical components reshoring push

What Patrick Dumont’s rise to CEO reveals about Las Vegas Sands Corp.’s post-founder strategy

Read More

6 minute read

Pharma Industry News

MBX Biosciences stock surges 160% after Canvuparatide Phase 2 success in hypoparathyroidism

MBX Biosciences (NASDAQ: MBX) jumps 160% after Canvuparatide Phase 2 success in hypoparathyroidism; see trial data, stock reaction, and Phase 3 outlook.

byPallavi Madhiraju

September 22, 2025

web analytics